Merrion Pharmaceuticals Technology to Be Used in Insulin Tablet Trial
May 29 2014 - 4:56AM
Dow Jones News
LONDON-- Merrion Pharmaceuticals PLC (3MP.DB) said Thursday that
drug group Novo Nordisk A/S (NVO) expects to use Merrion's drug
delivery technology GIPET in a trial for an insulin tablet.
-Merrion shares unchanged at 10 cents valuing the company at
EUR8.3 million.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024